RNS Number : 9286E
PureTech Health PLC
22 July 2016
|
For filings with the FCA include the annex
|
|
|
For filings with issuer exclude the annex
|
|
|
|
|
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi
|
|
|
|
|
1. Identity of the issuer or the underlying issuer of existing shares to which voting rights
are attached:ii
|
PureTech Health Plc
|
|
2 Reason for the notification (please tick the appropriate
box or boxes):
|
|
An acquisition or disposal of voting rights
|
X
|
|
An acquisition or disposal of qualifying financial instruments which may result in the acquisition of
shares already issued to which voting rights are attached
|
|
|
An acquisition or disposal of instruments with similar economic effect to qualifying financial
instruments
|
|
|
An event changing the breakdown of voting rights
|
|
|
Other (please specify):
|
|
|
|
3. Full name of person(s) subject to the
notification obligation:iii
|
Baillie Gifford & Co
|
|
4. Full name of shareholder(s)
(if different from 3.):iv
|
|
|
5. Date of the transaction and date on
which the threshold is crossed or
reached:v
|
20 July 2016
|
|
6. Date on which issuer notified:
|
21 July 2016
|
|
7. Threshold(s) that is/are crossed or
reached: vi, vii
|
5%
|
|
8. Notified details:
|
|
A: Voting rights attached to shares viii,
ix
|
|
Class/type of
shares
if possible using
the ISIN CODE
|
Situation previous
to the triggering
transaction
|
Resulting situation after the triggering transaction
|
|
Number
of
Shares
|
Number
of
Voting
Rights
|
Number
of shares
|
Number of voting
rights
|
% of voting rights x
|
|
Direct
|
Direct xi
|
Indirect xii
|
Direct
|
Indirect
|
|
Ordinary
Share
GB00BY2Z0H74
|
Below 5%
|
Below 5%
|
|
|
12,529,837
|
|
5.28%
|
|
|
|
|
|
B: Qualifying Financial Instruments
|
|
Resulting situation after the triggering transaction
|
|
Type of financial
instrument
|
Expiration
date xiii
|
Exercise/
Conversion Period xiv
|
Number of voting
rights that may be
acquired if the
instrument is
exercised/ converted.
|
% of voting
rights
|
|
N/A
|
|
|
|
|
|
|
|
C: Financial Instruments with similar economic effect to Qualifying Financial
Instruments xv, xvi
|
|
Resulting situation after the triggering transaction
|
|
Type of financial
instrument
|
Exercise price
|
Expiration date xvii
|
Exercise/
Conversion period xviii
|
Number of voting rights instrument refers to
|
% of voting rights xix, xx
|
|
N/A
|
|
|
|
|
Nominal
|
Delta
|
|
|
|
|
|
|
Total (A+B+C)
|
|
Number of voting rights
|
Percentage of voting rights
|
|
12,529,837
|
5.28%
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9. Chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held, if applicable: xxi
|
|
In the narrative below, the figures in [ ] indicate the amount of voting rights and the
percentage held by each controlled undertaking where relevant.
Baillie Gifford & Co, a discretionary investment manager, is the parent undertaking of
an investment management group.
Its wholly-owned subsidiary undertaking Baillie Gifford Overseas Limited
[3,421,563:1.44%] is also a discretionary investment manager.
Its wholly-owned subsidiary undertaking Baillie Gifford & Co Limited [4,011,350:1.69%]
is an OEIC Authorised Corporate Director and Unit Trust Manager which has delegated its discretionary investment
management role to Baillie Gifford & Co.
Its wholly-owned subsidiary undertaking Baillie Gifford Life Limited [1,697,490:0.72%] is a
life assurance company which procures discretionary investment management services from Baillie Gifford & Co in
respect of its own account shareholdings.
|
|
|
|
Proxy Voting:
|
|
10. Name of the proxy holder:
|
N/A
|
|
11. Number of voting rights proxy holder will cease to hold:
|
|
|
12. Date on which proxy holder will cease to hold voting rights:
|
|
|
|
|
13. Additional information:
|
|
|
14. Contact name:
|
Mike Bassi
|
|
15. Contact telephone number:
|
0131 275 3852
|
| |
|
|
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLRBMBTMBJTTAF